| No adjuvant therapy | Tamoxifen monotherapy | ||||
---|---|---|---|---|---|---|
Factors | Bcl-2 | Â | P-value | Bcl-2 | Â | P-value |
 | + (%) | - |  | + (%) | - |  |
Menopause | Â | Â | 0.0049* | Â | Â | 0.1249 |
Post | 156 (58) | 112 | Â | 191 (64) | 108 | Â |
Pre | 210 (70) | 92 | Â | 117 (71) | 48 | Â |
Tumor size | Â | 0.0023* | Â | 0.0051* | ||
>20Â mm | 199 (58) | 143 | Â | 178 (61) | 112 | Â |
≤20 mm | 204 (70) | 88 |  | 138 (74) | 49 |  |
Node | Â | 0.9049 | Â | 0.2938 | ||
+ | 96 (63) | 56 | Â | 141 (64) | 80 | Â |
- | 307 (64) | 175 | Â | 175 (68) | 81 | Â |
Grade | Â | <0.0001* | Â | 0.0040* | ||
II + III | 244 (54) | 205 |  | 170 (61) | 109 |  |
I | 157 (86) | 26 | Â | 145 (74) | 52 | Â |
ER | Â | <0.0001* | Â | <0.0001* | ||
+ | 330 (88) | 45 | Â | 290 (74) | 100 | Â |
- | 71 (28) | 186 | Â | 26 (30) | 61 | Â |
PR | Â | <0.0001* | Â | <0.0001* | ||
+ | 242 (89) | 30 | Â | 189 (76) | 59 | Â |
- | 159 (44) | 200 | Â | 127 (55) | 102 | Â |
HER2 | Â | <0.0001* | Â | Â 0.0005* | ||
+ | 19 (21) | 70 | Â | 8 (33) | 16 | Â |
- | 381 (70) | 160 | Â | 308 (68) | 145 | Â |
Total | 634 | Â | 477 | Â |